Podcasts about mass general hospital

In a special episode of TSC Now, Dan interviews Bridgett Langstaff, mom to Jude, a 17-year-old living with tuberous sclerosis complex (TSC) and epilepsy. Bridgett shares Jude’s diagnosis story and how they ultimately made their way to Mass General Hospital and Dr. Thiele. She also talks about Jude’s ongoing struggle with seizures, from infantile spasms as a baby, to partial seizures, to tonic clonic seizures as he started going through puberty, and she details their journey to achieve seizure control through multiple medications, the ketogenic diet, and surgery. Finally, she shares what it’s like as a parent to witness a prolonged seizure (one lasting longer than 3 minutes) and how and when they decide to administer rescue medication to stop a seizure. This podcast was sponsored by UCB Biopharma, in an effort to raise awareness of prolonged seizures. UCB was not involved in the content development for this podcast. UCB is currently running the STARS study, a clinical trial researching an investigational medication for people who experience prolonged epileptic seizures (i.e. lasting more than 3 minutes) who are over the age of 12. The STARS Study is testing an inhaler containing an investigational drug that has been designed to potentially stop a prolonged seizure once it has begun. If you are interested in learning more, visit www.starsepilepsystudy.com to learn more or contact a Patient Navigator to better understand this study at 470-523-2502.

What happens when an emergency medicine physician knows that the N95 mask she's wearing every day during the COVID-19 pandemic was invented by her great-grandfather over a century ago? Dr. Shan Liu joins me for a conversation that weaves together family legacy, innovation from the margins, and the power of storytelling to fight racism. Shan is an emergency medicine physician at Mass General Hospital, an associate professor at Harvard Medical School, and a children's book author. Her award-winning book, Masked Hero: How Wu Lien-teh Invented the Mask That Ended an Epidemic, tells the remarkable story of her great-grandfather who created the first respiratory mask during the 1910 Manchurian plague outbreak. Wu Lien-teh was the first Chinese Malaysian to study medicine at Cambridge, faced relentless racism throughout his career, and became the first Chinese person nominated for a Nobel Prize in medicine. Website: shanwuliu.com If you enjoy the show, please leave a ⭐⭐⭐⭐⭐ rating on Apple or a

In this episode, Alyssa and Nadia dive into a deeply personal conversation about aging, menopause, and what it means to be a woman as your body changes.Alyssa opens up about feeling younger than she looks at 48, sparking a discussion about how we perceive ourselves versus how we appear to others. The conversation quickly shifts to menopause and perimenopause — topics that dominate Alyssa's social media feed and conversations with friends her age. While hot flashes get all the attention, the reality includes forgetfulness, mood changes, sexual dysfunction, and vaginal dryness.Alyssa reveals that she missed her first period last month (and no, she's not pregnant). This milestone has her questioning whether to start hormone replacement therapy now or wait for symptoms. The research suggests HRT can protect brain health, bone density, and heart health — but Alyssa isn't someone who takes pills unless absolutely necessary.Nadia draws parallels between menopause symptoms and her own menstrual cycle experiences, noting how women are constantly attributing body changes, mood shifts, and physical symptoms to hormonal fluctuations. She reflects on doing multiple projects on women's health for school, discovering there's shockingly little research and funding in this area.The conversation takes a vulnerable turn as Alyssa grapples with what menopause means for her identity as a woman. Society has taught women that femininity means soft hair, a certain figure, attractiveness, and the ability to have babies. With menopause, many of these markers fade — hair thins, bodies change, fertility ends. It's messing with Alyssa's head, even though she knows logically these societal expectations shouldn't define her.Both agree that women face constant internal struggles and external pressures that men simply don't experience in the same way. But they also find empowerment in it — Nadia feels deeply in touch with her body because of her cycle, and Alyssa celebrates women's intuition, sensitivity, and the literal magic of creating human life.The episode wraps with Nadia sharing exciting news: she landed a co-op doing clinical research at Mass General Hospital, focusing on food insecurity, food banks, SNAP benefits, and Medicaid.TakeawaysLooking in the mirror can feel disorienting when you feel younger than you lookHot flashes are just the tip of the menopause iceberg — symptoms include forgetfulness, mood changes, pain with intercourse, and vaginal drynessHormone replacement therapy may protect brain health, bone density, and heart healthThere's a lack of research and funding for women's health issuesMenopause can trigger an identity crisis around femininity and societal expectations of womenWomen constantly attribute physical and emotional changes to hormonal fluctuations throughout their livesThe expectations and daily struggles women face are different from (though not necessarily harder than) what men experienceDespite the challenges, there's something empowering about being deeply in touch with your bodyWomen's intuition and the ability to create life are genuinely magicalChapters0:10–2:08 – Feeling Young But Looking Old 2:09–5:27 – Menopause on Social Media and the Symptoms No One Talks About 5:28–7:24 – Alyssa Misses Her First Period (And the Hormone Replacement Dilemma) 7:25–10:50 – Nadia's Perspective: Blaming Everything on Your Period 10:51–12:41 – What Menopause Means for Identity as a Woman 12:42–14:26 – Daily Internal Struggles: The Expectations Women Face 14:27–16:30 – The Magic of Being a Woman (Despite Everything) 16:31–17:51 – Nadia's Big News: Clinical Research Co-op at Mass General

Earlier this season, we visited the Ether Dome at the Massachusetts General Hospital to learn about the first public use of an anesthetic in surgery. On this bonus episode of The Object of History, we return to Mass General to visit the Paul S. Russell, MD Museum of Medical History and Innovation. MHS Podcast Producer Sam Hurwitz joins the Director of the Museum, Sarah Alger, for a tour where they examine some of the museum's most significant items related to the history of medicine. Learn more about episode objects here: https://www.masshist.org/podcast/season-4-bonus-episode-Russell-Museum  Email us at podcast@masshist.org. Listen to Episode 3 Episode Special Guest: Sarah Alger is the George and Nancy Putnam Director of Mass General Hospital's Paul S. Russell, MD Museum of Medical History and Innovation. She was a founding editor of Proto, a thought leadership publication that was sponsored by MGH for 17 years. This episode uses materials from: The Bond (Instrumental) by Chad Crouch (Attribution-NonCommercial 4.0 International)        Psychic by Dominic Giam of Ketsa Music (licensed under a commercial non-exclusive license by the Massachusetts Historical Society through Ketsa.uk)        Curious Nature by Dominic Giam of Ketsa Music (licensed under a commercial non-exclusive license by the Massachusetts Historical Society through Ketsa.uk)

BrainStorm wants to hear from you! Send us a text.Dr. Rachel Buckley of Mass General Hospital and Harvard Medical School discusses groundbreaking research revealing stark sex differences in Alzheimer's disease with BrainStorm host Meryl Comer. Her studies found that while men and women show similar levels of amyloid protein, women consistently display significantly higher levels of tau. This discovery has sparked a $50 million Welcome Leap Care grant aimed at cutting Alzheimer's lifetime risk among women by half.The episode clarifies widespread confusion about hormone replacement therapy, explaining that the problematic Women's Health Initiative study used outdated hormone formulations on women over 65—far past the optimal window for intervention. Dr. Buckley emphasizes that current evidence supports HRT use within certain parameters and stresses the importance of women advocating for themselves when experiencing perimenopause symptoms like brain fog and sleep disturbances. The research highlights menopause as a critical period that may influence Alzheimer's risk decades later.Support the show

In this episode, Moderator Dr. Scott Weiner learns how Dr. Sarah E. Wakeman's innovative role unites diverse stakeholders to change both culture and practice in SUD care. We explore best practices for medication for opioid use disorder (MOUD), the development of unified IT tools, and the fine balance between clinical support and alert fatigue. Dr. Wakeman highlights the importance of data and quality dashboards, plus how Medicaid and state funding are leveraged to sustain impactful initiatives. The episode offers practical inspiration, showing how collaboration and the right incentives can drive value—and save lives.  What You'll Learn Strategies for building system-wide, holistic SUD initiatives. How to engage stakeholders across health systems, from clinicians to IT to state agencies. Best practices for developing and updating MOUD order sets. Approaches to increasing provider comfort with life-saving opioid treatments. The balance of clinical decision support and alert fatigue. The role of data dashboards in tracking SUD outcomes and quality measures. How to leverage Medicaid and state funds to support and expand treatment resources. Insights into risk contracts, funding streams, and statewide efforts to prevent overdose deaths. Why this challenging work is both challenging and rewarding!  MODERATOR: Scott Weiner, MD, MPH, FAAEM, FACEP, FASAM Emergency and Addiction Medicine Physician, Brigham and Women's Hospital Associate Professor, Harvard Medical School  Dr. Weiner is the McGraw Distinguished Chair in the Department of Emergency Medicine at Brigham and Women's Hospital and an Associate Professor of Emergency Medicine at Harvard Medical School. He is board-certified in emergency medicine and addiction medicine. He is an active researcher, working on multiple projects that focus on prevention and treatment of opioid use disorder.  GUEST: Sarah Elizabeth Wakeman, MD Medical Director for Substance Use Disorder at Mass General Brigham Medical Director for the Mass General Hospital Substance Use Disorder Initiative Program director of the Mass General Addiction Medicine fellowship Associate Professor of Medicine at Harvard Medical School  Sarah E. Wakeman, MD is the Senior Medical Director for Substance Use Disorder at Mass General Brigham in the Office of the Chief Medical Officer, Medical Director for the Mass General Hospital Program for Substance Use & Addiction Services, Program Director of the Mass General Addiction Medicine fellowship, and an Associate Professor of Medicine at Harvard Medical School. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine and board certified in Addiction Medicine by the American Board of Preventive Medicine. Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include integrated substance use disorder treatment in general medical settings, low threshold treatment models, and opioid use disorder treatment. 

In 2001, Salem-native Ron Gaudette was working as a pharmacist at Mass General Hospital and had recently joined a group called the International Medical Surgical Response Team, which provides critical care to areas impacted by disasters. This specialized volunteer team was soon deployed to the World Trade Center, making it Gaudette's inaugural mission. He spent 11 days at Ground Zero and shared his experiences 24 years later.

Dr. Mike Pistiner is not just an allergist and immunologist, he's also an allergy dad and fierce patient advocate. In this episode, Dr. Mike breaks down what allergies are, typical signs and symptoms and how they're treated. Have you been curious about when is the right time to use epinephrine? Then this episode is for YOU! Tune in today!Michael Pistiner, MD, MMSc is Director of Food Allergy Advocacy, Education and Prevention for the MassGeneral Hospital for Children, Food Allergy Center. He has a special interest in food allergy and anaphylaxis education and advocacy, infant food allergy management,  healthcare provider education, facilitating collaborations between the medical home and school health, and maintaining quality of life in children (and their families) with food allergies.  Dr. Mike is author of "Everyday Cool With Food Allergies", co-author of the "Living Confidently With Food Allergy" handbook, and co-founder and content creator of AllergyHome.org.Dr. Pistiner is a fellow in the American Academy of Pediatrics (AAP), where he is a member of the Section on Allergy and Immunology Executive Committee, Council on School Health and the Massachusetts Chapter of the AAP. He is also a member of the American Academy of Allergy Asthma & Immunology and the American College of Allergy, Asthma and Immunology.Additionally, he serves on the medical advisory board of Asthma & Allergy Foundation of America, New England Chapter and is a voluntary consultant for the Massachusetts Department of Public Health School Health Service Unit.To learn more about the Food Allergy Management Bootcamp at MassGeneral visit: https://www.massgeneral.org/children/food-allergies/food-allergy-management-boot-campTo learn more about the FAMP-It resource visit: https://famp-it.org/

Mike and Cam are excited to welcome Dr. Maureen Leonard back to the podcast! Dr. Leonard is Clinical Director of the Center For Celiac Research and Treatment at Mass General Hospital for Children (MGHfC) and an Assistant Professor of Pediatrics at Harvard Medical School (HMS). Dr. Leonard shares an update on her groundbreaking work on the CDGEMM study, which follows infants from birth through childhood to learn more about the many factors that can contribute to the development of celiac disease. She shares her thoughts on some of the other exciting advancements that are taking place in celiac research and treatment. Plus, Mike and Cam find out about how she navigates her busy life as a doctor living with celiac disease.

On today's Celiac Project Podcast:Mike and Cam are excited to welcome Dr. Maureen Leonard back to the podcast! Dr. Leonard is Clinical Director of the Center For Celiac Research and Treatment at Mass General Hospital for Children (MGHfC) and an Assistant Professor of Pediatrics at Harvard Medical School (HMS). Dr. Leonard shares an update on her groundbreaking work on the CDGEMM study, which follows infants from birth through childhood to learn more about the many factors that can contribute to the development of celiac disease. She shares her thoughts on some of the other exciting advancements that are taking place in celiac research and treatment. Plus, Mike and Cam find out about how she navigates her busy life as a doctor living with celiac disease.Listen to the full episode here: https://celiacprojectpodcast.libsyn.com/I would love to hear from you! Leave your messages for Andrea at contact@baltimoreglutenfree.com and check out www.baltimoreglutenfree.comInstagramFacebookGluten Free College 101Website: www.glutenfreecollege.comFacebook: http://www.Facebook.com/Glutenfreecollege Hosted on Acast. See acast.com/privacy for more information.

Vidcast:  https://www.instagram.com/p/DMYXNKuvaTI/Adolescent vapers taking the drug varenicline, branded as Chantix, were 8 times more likely to abandon the practice compared with those receiving behavioral counseling and a quit-vaping text program.  This the finding from a study by Harvard's Mass General Hospital psychiatrists studying addiction in young adults.Their trial included 261 adolescents 16 to 25 receiving either the test drug, a placebo drug, or conventional counseling over a 3 month period.   When the data were tabulated, 51% of those on varenicline had completely stopped vaping, compared with 14% in the placebo group, and about 6% receiving counseling.  The effect was lasting with more than half of the Chantix group remaining vape-free 6 months after stopping therapy.With 1.6 million American middle and high school kids vaping in 2024 according to the CDC, an effective medication to help drive vaping cessation is more than welcome.  Chantix is a prescription drug, so parents do speak with your child's pediatric team about obtaining it if your child has an e-cigarette habit to kick.https://jamanetwork.com/journals/jama/fullarticle/2833137#vaping #teens #chantix #varenicline #cessation

In this week's episode, we dig into two deceptively simple questions: When does someone become a cancer survivor, and should palliative care be in the business of caring for them? Spoiler: It's more complicated than it seems. We've invited two palliative care doctors to talk about survivorship with us: Laura Petrillo, a physician-researcher at Mass General Hospital and Harvard Medical School, and Laura Shoemaker, an outpatient palliative care doctor at the Cleveland Clinic. This episode is a must-listen for those navigating the evolving landscape of cancer care, and asking not just how we treat cancer, but how we support people who are living with it.  If you want some further reading on survivorship, check out some of these articles: A NEJM article titled “Time to Study Metastatic-Cancer Survivorship” A ASCO publication that includes a section on survivorship - Patient-Centered Palliative Care for Patients With Advanced Lung Cancer A webinar on survivorship - Blending Survivorship and Palliative Care (NCI)

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

Jerome was diagnosed with muscle invasive bladder cancer on January 29, 1997. The diagnosis was based on a transurethral resection surgery. Having done his research, he contacted a doctor at Harvard and Mass General Hospital about a clinical trial for a bladder sparing protocol. To Jermoe's surprise, Dr.Shipley called back and shared the protocol with Jerome's medical team and the treatment began a couple of weeks later. The treatment involved chemotherapy in conjunction with radiation therapy.  Jerome experienced several recurrences over the years, each time treating them with surgery and infusions. In 2018 a recurrence involved hospitalization and tubes were placed in each kidney. This time Jerome was faced with a decision to have a radical cystectomy or given the choice to do immunotherapy. By 2019 there was little evidence of bladder cancer and infusions continued, with no side effects. He still has a tube in one kidney and is otherwise thriving! email: Jerome@mountainsangha.org phone: 415-299-0428 website: www.mountainsangha.org Book: Healing with the 7 Principles of Mindfulness, by Jerome FreedmanHere is what Dr. Kelly Turner, PhD has to say about Healing with the 7 Principles of Mindfulness: “Dr. Freedman speaks from experience, both as a cancer survivor himself, and the father of a Radical Remission cancer survivor. His book, “Healing with the 7 Principles of Mindfulness” gives readers a nurturing, helping hand throughout the entire cancer journey, especially with regard to developing a meditation practice. –Kelly Turner, PhD, Author of the NYTimes Bestseller “Radical Remission: Surviving Cancer Against All Odds” Stop Cancer in Its Tracks: How to Embrace Mindfulness In Healing by Jerome Freedman ___________________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube __________________________ Thank you to our friends from The Healing Oasis for sponsoring this episode of the podcast.  The Healing Oasis is a first of its kind in beautiful British Columbia, Canada where we encourage the body to heal from cancer using alternative therapies & cancer fighting meals at a wellness retreat center in nature. Our top naturopathic cancer doctor will prescribe a protocol tailored specifically for you. There's no place quite like it. Start your healing journey today! Learn More about The Healing Oasis by visiting these links: Website   Testimonials Video Overview

Episode OverviewIn this episode, Kristen interviews Erin Schultz, founder of Her Personal Finance, about building a successful niche business serving women in medicine, tech, and law. Erin shares her journey from Harvard Business School graduate to personal finance educator and financial planner, discussing how she built an audience on social media and the power of niching down.Guest BioErin Schultz is the founder of Her Personal Finance (founded in 2015). She's a Harvard Business School graduate who specializes in helping physicians and research scientists balance student loan payments with retirement savings. Her online classes are offered in partnership with Mass General Hospital, and she has helped hundreds of clients navigate hospital benefits and financial planning.Timestamps[00:00] Introduction to Erin Schultz[01:15] Erin's Journey from Harvard to Personal Finance[03:54] Building a Social Media Presence[04:58] Engaging with Content and Community[08:19] The Importance of Niching Down[10:33] Personal Stories and Professional Connections[19:31] Adapting Content for Different Platforms[22:34] Resources and Final ThoughtsKey Takeaways1. Niche down ruthlessly - Erin's focus on women in specific high-earning professions allows her to become a true expert2. Personal stories drive engagement - Educational content performs worse than personal narratives3. Be approachable, not traditional - Standing out from "dusty old guys from Fidelity"4. Repurpose content strategically - Same story, different formats for different platforms5. Address real pain points - Fertility costs, childcare planning, student loansConnect with Erin- Instagram: [@herpersonalfinance](https://instagram.com/herpersonalfinance)- LinkedIn: [Erin Schultz](https://linkedin.com/in/erinschultz)- Website: [herpersonalfinance.com](http://herpersonalfinance.com)- Bimonthly newsletter covering topics like car payments, 401(k)s, and student loans

A shooting outside Mass General Hospital shuts down roads for a time in Boston, the White House takes another shot at Harvard, and public defenders gather at the State House. Stay in "The Loop" with #iHeartRadio.

As artificial intelligence (AI) tools become increasingly mainstream, they can potentially transform neurology clinical practice by improving patient care and reducing clinician workload. Critically evaluating these AI tools for clinical practice is important for successful implementation. In this episode, Katie Grouse, MD, FAAN speaks with Peter Hadar, MD, MS, coauthor of the article “Clinical Applications of Artificial Intelligence in Neurology Practice” in the Continuum® April 2025 Neuro-ophthalmology issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Hadar is an instructor of neurology at Harvard Medical School and an attending physician at the Massachusetts General Hospital in Boston, Massachusetts. Additional Resources Read the article: Clinical Applications of Artificial Intelligence in Neurology Practice Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @PeterNHadar Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Peter Hadar about his article on clinical applications of artificial intelligence in neurology practice, which he wrote with Dr Lydia Moura. This article appears in the April 2025 Continuum issue on neuro-ophthalmology. Welcome to the podcast, and please introduce yourself to our audience. Dr Hadar: Hi, thanks for having me on, Katie. My name is Dr Peter Hadar. I'm currently an instructor over at Mass General Hospital, Harvard Medical School, and I'm excited to talk more about AI and how it's going to change our world, hopefully for the better. Dr Grouse: We're so excited to have you. The application of AI in clinical practice is such an exciting and rapidly developing topic, and I'm so pleased to have you here to talk about your article, which I found to be absolutely fascinating. To start, I'd like to hear what you hope will be the key takeaway from your article with our listeners. Dr Hadar: Yeah, thank you. The main point of the article is that AI in medicine is a tool. It's a wonderful tool that we should be cautiously optimistic about. But the important thing is for doctors, providers to be advocates on their behalf and on behalf of their patients for the appropriate use of this tool, because there are promises and pitfalls just with any tool. And I think in the article we detail a couple ways that it can be used in diagnostics, in clinical documentation, in the workflow, all ways that can really help providers. But sometimes the devil is in the details. So, we get into that as well. Dr Grouse: How did you become interested in AI and its application, specifically in the practice of neurology? Dr Hadar: When I was a kid, as most neurologists are, I was- I nerded out on a lot of sci-fi books, and I was really into Isaac Asimov and some of his robotics, which kind of talks about the philosophy of AI and how AI will be integrated in the future. As I got into neurology, I started doing research neurology and a lot of folks, if you're familiar with AI and machine learning, statistics can overlap a lot with machine learning. So slowly but surely, I started using statistical methods, machine learning methods, in some of my neurology research and kind of what brought me to where I am today. Dr Grouse: And thinking about and talking about AI, could you briefly summarize a few important terms that we might be talking about, such as artificial intelligence, generative AI, machine learning, etcetera? Dr Hadar: It's a little difficult, because some of these terms are nebulous and some of these terms are used in the lay public differently than other folks would use it. But in general, artificial intelligence is kind of the ability of machines or computers to communicate independently. It's similar to as humans would do so. And there are kind of different levels of AI. There's this very hard AI where people are worried about with kind of terminator-full ability to replicate a human, effectively. And there are other forms of narrow AI, which are actually more of what we're talking about today, and where it's very kind of specific, task-based applications of machine learning in which even if it's very complex, the AI tools, the machine learning tools are able to give you a result. And just some other terms, I guess out there. You hear a lot about generative AI. There's a lot of these companies and different algorithms that incorporate generative AI, and that usually kind of creates something, kind of from scratch, based on a lot of data. So, it can create pictures, it can create new text if you just ask it. Other terms that can be used are natural language processing, which is a big part of some of the hospital records. When AI tools read hospital records and can summarize something, if it can translate things. So, it turns human speech into these results that you look for. And I guess other terms like large language models are something that also have come into prominence and they rely a lot on natural language processing, being able to understand human speech, interpret it and come up with the results that you want. Dr Grouse: Thank you, that's really helpful. Building on that, what are some of the current clinical applications of AI that we may already be using in our neurologic practice and may not even be aware that that's what that is? Dr Hadar: It depends on which medical record system you use, but a very common one are some of the clinical alerts that people might get, although some of them are pretty basic and they can say, you know, if the sodium is this level, you get an alert. But sometimes they do incorporate fancier machine learning tools to say, here's a red flag. You really should think about contacting the patient about this. And we can talk about it as well. It might encourage burnout with all the different flags. So, it's not a perfect tool. But these sorts of things, typically in the setting of alerts, are the most common use. Sorry, and another one is in folks who do stroke, there are a lot of stroke algorithms with imaging that can help detect where the strokes occur. And that's a heavy machine learning field of image processing, image analysis for rapid detection of stroke. Dr Grouse: That's really interesting. I think my understanding is that AI has been used specifically for radiology interpretation applications for some time now. Is that right? Dr Hadar: In some ways. Actually, my background is in neuroimaging analysis, and we've been doing a lot of it. I've been doing it for years. There's still a lot of room to go, but it's really getting there in some ways. My suspicion is that in the coming years, it's going to be similar to how anesthesiologists at one point were actively bagging people in the fifties, and then you develop machines that can kind of do it for you. At some point there's going to be a prelim radiology read that is not just done by the resident or fellow, but is done by the machine. And then another radiologist would double check it and make sure. And I think that's going to happen in our lifetime. Dr Grouse: Wow, that's absolutely fascinating. What are some potential applications of AI in neurologic practice that may be most high-yield to improve patient care, patient access, and even reduce physician burnout? Dr Hadar: These are separate sort of questions, but they're all sort of interlinked. I think one of the big aspects of patient care in the last few years, especially with the electronic medical record, is patients have become much more their own advocates and we focus a lot more on patient autonomy. So, they are reaching out to providers outside of appointments. This can kind of lead to physician burnout. You have to answer all these messages through the electronic medical record. And so having, effectively, digital twins of yourself, AI version of yourself, that can answer the questions for the patient on your off times is one of the things that can definitely help with patient care. In terms of access, I think another aspect is having integrated workflows. So, being able to schedule patients efficiently, effectively, where more difficult patients automatically get one-hour appointments, patients who have fewer medical difficulties might get shorter appointments. That's another big improvement. Then finally, in terms of physician burnout, having ambient intelligence where notes can be written on your behalf and you just need to double-check them after allows you to really have a much better relationship with the patients. You can actually talk with them one on one and just focus on kind of the holistic care of the patient. And I think that's- being less of a cog in the machine and focusing on your role as a healer would be actually very helpful with the implementation of some of these AI tools. Dr Grouse: You mentioned ambient technology and specifically ambient documentation. And certainly, this is an area that I feel a lot of excitement about from many physicians, a lot of anticipation to be able to have access to this technology. And you mentioned already some of the potential benefits. What are some of the potential… the big wins, but then also potential drawbacks of ambient documentation? Dr Hadar: Just to kind of summarize, the ambient intelligence idea is using kind of an environmental AI system that, without being very obtrusive, just is able to record, able to detect language and process it, usually into notes. So, effectively like an AI scribe that is not actually in the appointment. So, the clear one is that---and I've seen this as well in my practice---it's very difficult to really engage with the patient and truly listen to what they're saying and form that relationship when you're behind a computer and behind a desk. And having that one-on-one interaction where you just focus on the patient, learn everything, and basically someone else takes notes for you is a very helpful component of it. Some of the drawbacks, though, some of it has to do with the existing technology. It's still not at the stage where it can do everything. It can have errors in writing down the medication, writing down the exact doses. It can't really, at this point, detect some of the apprehensions and some of the nonverbal cues that patients and providers may kind of state. Then there's also the big one where a lot of these are still done by startups and other companies where privacy may be an issue, and a lot of patients may feel very uncomfortable with having ambient intelligence tools introduced into their clinical visit, having a machine basically come between the doctor and the patient. But I think that over time these apprehensions will lessen. A lot of the security will improve and be strengthened, and I think that it's going to be incorporated a lot more into clinical practice. Dr Grouse: Yeah, well, we'll all be really excited to see how that technology develops. It certainly seems like it has a lot of promise. You mentioned in your article a lot about how AI can be used to improve screening for patients for certain types of conditions, and that certainly seems like an obvious win. But as I was reading the article, I couldn't help but worry that, at least in the short term, these tools could translate into more work for busy neurologists and more demand for access, which is, you know, already, you know, big problems in our field. How can tools like these, such as, like, for instance, the AI fundoscopic screening for vascular cognitive risk factors help without adding to these existing burdens? Dr Hadar: It's a very good point. And I think it's one of the central points of why we wanted to write the article is that these AI in medicine, it's, it's a tool like any other. And just like when the electronic medical record came into being, a lot of folks thought that this was going to save a lot of time. And you know, some people would say that it actually worsened things in a way. And when you use these diagnostic screening tools, there is an improvement in efficiency, there is an improvement in patient care. But it's important that doctors, patients advocate for this to be value-based and not revenue-based, necessarily. And it doesn't mean that suddenly the appointments are shorter, that now physicians have to see twice as many patients and then patients just have less of a relationship with their provider. So, it's important to just be able to integrate these tools in an appropriate way in which the provider and the patient both benefit. Dr Grouse: You mentioned earlier about the digital twin. Certainly, in your article you mentioned, you know, that idea along with the idea of the potential of development of virtual chatbot visits or in-person visits with a robot neurologist. And I read all this with equal parts, I think excitement, but horror and and fear. Can you tell us more about what these concepts are, and how far are we from seeing technology like this in our clinics, and maybe even, what are the risks we need to be thinking about with these? Dr Hadar: Yeah. So, I mean, I definitely think that we will see implementation of some of these tools in our lifetime. I'm not sure if we're going to have a full walking, talking robot doing some of the clinical visits. But I do think that, especially as we start doing a lot more virtual visits, it is very easy to imagine that there will be some sort of video AI doctor that can serve as, effectively, a digital twin of me or someone else, that can see patients and diagnose them. The idea behind the digital twin is that it's kind of like an AI version of yourself. So, while you only see one patient, an AI twin can go and see two or three other patients. They could also, if the patients send you messages, can respond to those messages in a way that you would, based on your training and that sort of thing. So, it allows for the ability to be in multiple places at once. One of the risks of this is, I guess, overreliance on the technology, where if you just say, we're just going to have a chatbot do everything for us and then not look at the results, you really run the risk of the chatbot just recommending really bad things. And there is training to be had. Maybe in fifty years the chatbot will be at the same level as a physician, but there's still a lot of room for improvement. I personally, I think that my suspicion as to where things will go are for very simple visits in the future and in our lifetime. If someone is having a cold or something like that and it goes to their primary care physician, a chatbot or something like that may be of really beneficial use. And it'll help segment out the different groups of simple diagnosis, simple treatments can be seen by these robots, these AI, these machine learning tools; and some of the more complex ones, at least for the early implementation of this will be seen by more specialized providers like neurologists and subspecialist neurologists too. Dr Grouse: That certainly seems reasonable, and it does seem that the more simple algorithmic things are always where these technologies will start, but it'll be interesting to see where things can go with more complex areas. Now I wanted to switch gears a little bit in the article- and I thought this was really important because I see it as being certainly one of the bigger drawbacks of AI, is that despite the many benefits of artificial intelligence, AI can unfortunately perpetuate systemic bias. And I'm wondering if you could tell us a little bit more about how this happened? Dr Hadar: I know I'm beating a dead horse on this, but AI is a tool like any other. And the problem with it is that what you put in is very similar to what you get out. And there's this idea in computer science of “garbage in, garbage out”. If you include a lot of data that has a lot of systemic biases already in the data, you're going to get results that perpetuate these things. So, for instance, if in dermatologic practices, if you just had a data set that included people of one skin color or one race and you attempted to train a model that would be able to detect skin cancer lesions, that model may not be easily applicable to people of other races, other ethnicities, other skin colors. And that can be very damaging for care. And it can actually really, really hurt the treatments for a lot of the patients. So that is one of the, kind of, main components of the systemic biases in AI. The way we mitigate them is by being aware of it and actually implementing, I guess, really hard stops on a lot of these tools before they get into practice. Being sure, did your data set include this breakdown of sex and gender, of race and ethnicity? So that the stuff you have in the AI tool is not just a very narrow, focused application, but can be generalized to a large population, not just of one community, one ethnic group, racial group, one country, but can really be generalized throughout the world for many patients. Dr Grouse: The first step is being aware of it, and hopefully these models will be built thoughtfully to help mitigate this as much as possible. I wanted to ask as well, another concern about AI is the safety of private data. And I'm wondering, as we're starting to do things like use ambient documentation, AI scribe, and other types of technologies like this, what can we tell our patients who are concerned about the safety of their personal data collected via these programs, particularly when they're being stored or used with outside companies that aren't even in our own electronic medical records system? Dr Hadar: Yeah, it's a very good question, and I think it's one of the major limitations of the current implementation of AI into clinical practice, because we still don't really have great standards---medical standards, at least---for storing this data, how to analyze this data. And my suspicion is that at some point in the future, we're going to need to have a HIPAA compliance that's going to be updated for the 21st century, that will incorporate the appropriate use of these tools, the appropriate use of these data storage, of data storage beyond just PHI. Because there's a lot more that goes into it. I would say that the important thing for how to implement this, and for patients to be aware of, is being very clear and very open with informed consent. If you're using a company that isn't really transparent about their data security and their data sharing practices, that needs to be clearly stated to the patient. If their data is going to be shared with other people, reanalyzed in a different way, many patients will potentially consider not participating in an AI implementation in clinic. And I think the other key thing is that this should be, at least initially, an opt-in approach as opposed to an opt-out approach. So patients really have- can really decide and have an informed opinion about whether or not they want to participate in the AI implementation in medicine. Dr Grouse: Well, thank you so much for explaining that. And it does certainly sound like there's a lot of development that's going to happen in that space as we are learning more about this and the use of it becomes more prevalent. Now, I also wanted to ask, another good point that you made in your article---and I don't think comes up enough in this area, but likely will as we're using it more---AI has a cost, and some of that cost is just the high amount of data and computational processing needed to use it, as well as the effects on the environment from all this energy usage. Given this drawback of AI, how can we think about potential costs versus the benefits, the more widespread use of this technology? Or how should we be thinking about it? Dr Hadar: It's part of a balance of the costs and benefits, effectively, is that AI---and just to kind of name some of them, when you have these larger data centers that are storing all this data, it requires a lot of energy consumption. It requires actually a lot of water to cool these things because they get really hot. So, these are some of the key environmental factors. And at this point, it's not as extreme as it could be, but you can imagine, as the world transitions towards an AI future, these data centers will become huge, massive, require a lot of energy. And as long as we still use a lot of nonrenewable resources to power our world, our civilization, I think this is going to be very difficult. It's going to allow for more carbon in the atmosphere, potentially more climate change. So, being very clear about using sustainable practices for AI usage, whether it be having data centers specifically use renewable resources, have clear water management guidelines, that sort of thing will allow for AI to grow, but in a sustainable way that doesn't damage our planet. In terms of the financial costs… so, AI is not free. However, on a given computer, if you want to run some basic AI analysis, you can definitely do it on any laptop you have and sometimes even on your phone. But for some of these larger models, kind of the ones that we're talking about in the medical field, it really requires a lot of computational power. And this stuff can be very expensive and can get very expensive very quickly, as anyone who's used any of these web service providers can attest to. So, it's very important to be clear-eyed about problems with implementation because some of these costs can be very prohibitive. You can run thousands and you can quickly rack up a lot of money for some very basic analysis if you want to do it in a very rapid way, in a very effective way. Dr Grouse: That's a great overview. You know, something that I think we're all going to be having to think about a lot more as we're incorporating these technologies. So, important conversations I hope we're all having, and in our institutions as we're making these decisions. I wanted to ask, certainly, as some of our listeners who may be still in the training process are hearing you talk about this and are really excited about AI and implementation of technology in medicine, what would you recommend to people who want to pursue a career in this area as you have done? Dr Hadar: So, I think one of the important things for trainees to understand are, there are different ways that they can incorporate AI into their lives going forward as they become more seasoned doctors. There are clinical ways, there are research ways, there are educational ways. A lot of the research ways, I'm one of the researchers, you can definitely incorporate AI. You can learn online. You can learn through books about how to use machine learning tools to do your analysis, and it can be very helpful. But I think one of the things that is lacking is a clinician who can traverse both the AI and patient care fields and be able to introduce AI in a very effective way that really provides value to the patients and improves the care of patients. So that means if a hospital system that a trainee is eventually part of wants to implement ambient technology, it's important for physicians to understand the risks, the benefits, how they may need to adapt to this. And to really advocate and say, just because we have this ambient technology doesn't mean now we see fifty different patients, and then you're stuck with the same issue of a worse patient-provider relationship. One of the reasons I got into medicine was to have that patient-provider interaction to not only be kind of a cog in the hospital machine, but to really take on a role as a healer and a physician. And one of the benefits of these AI tools is that in putting the machine in medicine, you can also put the humanity back in medicine at times. And I think that's a key component that trainees need to take to heart. Dr Grouse: I really appreciate you going into that, and sounds like there's certainly need. Hoping some of our listeners today will consider careers in pursuing AI and other types of technologies in medicine. I really appreciate you coming to talk with us today. I think this is just such a fascinating topic and an area that everybody's really excited about, and hoping that we'll be seeing more of this in our lives and hopefully improving our clinical practice. Thank you so much for talking to us about your article on AI in clinical neurology. It was a fascinating topic and I learned a lot. Dr Hadar: Thank you very much. I really appreciate the conversation, and I hope that trainees, physicians, and others will gain a lot and really help our patients through this. Dr Grouse: So again, today I've been interviewing Dr Peter Hadar about his article on clinical applications of artificial intelligence in neurology practice, which he wrote with Dr Lydia Moura. This article appears in the most recent issue of Continuum on neuro-ophthalmology. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

You can text us here with any comments, questions, or thoughts!In this episode, Kemi welcomes Dr. Allison Wu. Dr. Wu is Principal Investigator of the Wunderfull Lab. She is a clinician-researcher board certified in pediatric gastroenterology and nutrition as well as obesity medicine. Her research focuses on epidemiology and health services research in pediatric nutrition and obesity. She completed her fellowship in Pediatric Gastroenterology, Hepatology & Nutrition at Boston Children's Hospital and the Harvard-wide Pediatric Health Services Research Fellowship at Mass General Hospital for Children. She is also an alumnus of our Get That Grant® coaching program! Together, they explore Dr. Wu's unique journey that intertwines her love for science, nutrition, and working with children, shaped by her family's background in academia and the restaurant business. Join the conversation as Dr. Wu shares her experiences with coaching, her insights on how supportive environments can foster growth, confidence, and collaboration and the importance of grant writing in creating meaningful change. Conversation Highlights: Navigating maternity leave and career transitions The role of coaching in professional growth Building community and collaboration in academia The importance of intentionality in career development  Loved this convo? Please go find Dr. Wu on LinkedIn to show her some love!  

The first two episodes in this Healthcare is Hard podcast series on “Opportunities in Oncology” explored the relationship between academic medical centers and community care, with guests Dr. Stephen Schleicher from Tennessee Oncology, and Dr. Harlan Levine from City of Hope. For the third and final episode in the series, Dr. Daphne Haas-Kogan joined Keith Figlioli for a conversation that dives more deeply into patient care, innovations in care delivery and the opportunities for entrepreneurs.Dr. Haas-Kogan is Chair of the Department of Radiation Oncology at Mass General Hospital, Brigham and Women's Hospital, and Boston Children's Hospital. She is also the Willem and Corrie Hees Family Professor of Radiation Oncology at Harvard Medical School.Dr. Haas-Kogan received her undergraduate degree in biochemistry and molecular biology from Harvard University and her medical degree at UCSF. She completed her residency in radiation oncology at UCSF in 1997 and became vice-chair for research at UCSF in 2003, and educational program director in 2008. Dr. Haas-Kogan's laboratory research focuses on molecular underpinnings of brain tumors and pediatric cancers. She leads large multi-institutional initiatives funded by NIH/NCI, philanthropic organizations, and industry collaborators.For this episode of Healthcare is Hard, some of the topics Dr. Haas-Kogan discussed with Keith include:The collaborative approach to care. Dr. Haas-Kogan talked about how most people with cancer struggle with many other medical issues – some predating cancer diagnosis, some precipitated by the treatment itself – and how several care teams are required to treat the patient wholistically. She also discussed how important it is for academic medical centers and community hospitals to work together, the responsibilities each holds to the patient, and the goal of making sure patients receive the same exact care regardless of location.The precision of radiation oncology. There are generally three pillars of cancer treatment. The first is surgery to remove tumors, the second is medication to kill cancer cells with drugs, and the third is radiation therapy to destroy cancer cells. Dr. Haas-Kogan described how radiation oncology is, in many ways, a combination of surgical oncology and medical oncology. It requires the precision of surgery – especially when treating a tumor close to critical structures like the brain stem or spinal cord – but can also be applied in a single day or over the course of weeks, similar to medication. She discussed how this allows for unique collaboration between academic researchers and community physicians, along with opportunities for creative workforce solutions.AI in oncology. The impact artificial intelligence has already had on oncology would have been unimaginable five or 10 years ago, and Dr. Haas-Kogan says the opportunities for entrepreneurs in the space are huge. As an example of the impact AI has already made, she talked about how radiation oncologists traditionally spend hours defining exactly what they want treated and the dose of radiation required. But now, AI is doing most of that, saving physicians precious time. She talked about how medicine is an art and how treatment like this is very nuanced, so she very often makes changes after reviewing AI-generated recommendations. But she says advancements are coming quickly.To hear Dr. Haas-Kogan and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

Kat Koppett is the Eponymous Founder of Koppett, a consultancy specializing in the use of improv and storytelling techniques to enhance individual and group performance. She has worked with diverse clients including Meta, Apple, Prezi, PwC, NASA, Havas Health, Mass General Hospital, the United Nations and the Clinton Global Initiative.Her book Training to Imagine: Practical Improvisational Theatre Techniques to Enhance Creativity, Teamwork, Leadership, and Learning , is considered a seminal work in the field of Applied Improv and is used by professionals around the world. She has given two TEDx talks on the use of improv to enhance non-theatrical performance.In 2019, Kat was the winner of the North American Simulation and Gaming Association (NASAGA)'s Ifill-Reynold's Lifetime Achievement Award. She is the co-director and a performing member of the Mopco Improv Theatre, a founding member and the current vice-president of the Applied Improvisation Network, and the co-host of the podcast, Performance Shift: The Art of Successfully Navigating Change.Give this a listen! Hosted on Acast. See acast.com/privacy for more information.

Dr. Ben Kleinstiver, whose lab is located at the Center for Genomic Medicine at Mass General Hospital, joins us to talk about programmable nucleases, genome editing, and the applications of this technology in the future of healthcare.

(00:00) The guys discuss the Four Nation’s Faceoff Tournament and Team USA’s and Bruins’ defenseman Charlie McAvoy being hospitalized at Mass General Hospital and will miss the championship game against Team Canada back in the United States on Thursday night. (11:31) Zo and Beetle address the news from yesterday about the Cincinnati Bengals putting the franchise tag on wide receiver Tee Higgins and what this means for the Patriots going forward with potentially pursuing a deal for the all-pro route-runner. (26:01) The guys discuss Mike Breer saying teams with cap space and draft picks should call the Cowboys about acquiring Micah Parsons and if the Patriots should be all-in on Parsons. (33:48) The guys finish out the hour by circling back to the Four Nation’s Faceoff and which nations should be represented in next year's rendition of the tournament.

In this episode, we visit the Bulfinch Building at the Massachusetts General Hospital to examine one of the most, if not the most, significant discoveries in modern medicine. Sarah Alger, the Director of the Paul S. Russell, MD Museum of Medical History and Innovation, shows us the hospital's Ether Dome where the first public surgery using an anesthetic was performed. Back at the MHS, we sit down with Chief Historian Peter Drummey and Curator of Art and Artifacts Emerita Anne Bentley to learn more about the contentious history of this innovation. Learn more about episode objects here: https://www.masshist.org/podcast/season-4-episode-3-painless-revolution Email us at podcast@masshist.org. Episode Special Guest: Sarah Alger is the George and Nancy Putnam Director of Mass General Hospital's Paul S. Russell, MD Museum of Medical History and Innovation. She was a founding editor of Proto, a thought leadership publication that was sponsored by MGH for 17 years. This episode uses materials from: The Bond (Instrumental) by Chad Crouch (Attribution-NonCommercial 4.0 International)        Psychic by Dominic Giam of Ketsa Music (licensed under a commercial non-exclusive license by the Massachusetts Historical Society through Ketsa.uk)        Curious Nature by Dominic Giam of Ketsa Music (licensed under a commercial non-exclusive license by the Massachusetts Historical Society through Ketsa.uk)

In this episode of BrainStorm host Meryl Comer continues her compelling interview with "Rockstar of Science" Dr. Rudy Tanzi, the pioneering Director of the Genetics and Aging Research Unit and Director of the McCance Center for Brain Health at Mass General Hospital. Dr. Tanzi unveils the secrets of brain health and Alzheimer's research. Exploring his innovative SHIELD framework, Dr. Tanzi offers practical strategies for cognitive wellness, from sleep and stress management to diet and lifelong learning.The episode takes an innovative turn with AI-generated questions that probe the challenges of Alzheimer's research. Dr. Tanzi provides candid insights into prevention, early intervention, and the future of medical science, sharing an unexpectedly optimistic view of combating cognitive decline. Blending scientific expertise with actionable advice, this episode is a must-listen for anyone interested in brain health, aging, and medical innovation.Support the show

Join BrainStorm host Meryl Comer as she kicks off 2025 with "Rockstar of Science" Dr. Rudy Tanzi, the pioneering Director of Genetics and Aging Research and Director of the McCance Center for Brain Health at Mass General Hospital. Dr. Tanzi delves into the new FDA-approved drugs, early cognitive blood tests, and why treating Alzheimer's should mirror our approach to heart disease by focusing on prevention long before symptoms appear. Drawing from his decades of research, Dr. Tanzi shares his vision for the future: a simple daily pill that could prevent Alzheimer's just like statins prevent heart disease. Whether you are concerned about brain health or fascinated by cutting-edge medical science, this episode offers hope and practical wisdom from one of the field's most influential voices. You don't want to miss it!Support the show

Like tens of millions of people, Stephen Dubner thought he had a penicillin allergy. Like the vast majority, he didn't. This misdiagnosis costs billions of dollars and causes serious health problems, so why hasn't it been fixed? And how about all the other things we think we're allergic to? SOURCES:Kimberly Blumenthal, allergist-immunologist and researcher at Mass General Hospital and Harvard Medical School.Theresa MacPhail, associate professor of science and technology studies at Stevens Institute of Technology.Thomas Platts-Mills, professor of medicine at the University of Virginia.Elena Resnick, allergist and immunologist at Mount Sinai Hospital. RESOURCES:Allergic: Our Irritated Bodies in a Changing World, by Theresa MacPhail (2023)."Evaluation and Management of Penicillin Allergy: A Review," by Erica S. Shenoy, Eric Macy, and Theresa Rowe (JAMA, 2019)."The Allergy Epidemics: 1870–2010," by Thomas Platts-Mills (The Journal of Allergy and Clinical Immunology, 2016)."Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy," by George Du Toit, Graham Roberts, et al. (The New England Journal of Medicine, 2015). EXTRAS:Freakonomics, M.D.

Chime In, Send Us a Text Message!In this episode, we explore the critical role of social determinants of health (SDOH) in stroke prevention and recovery with an incredible panel of experts from the Bugher Collaborative. Our guests include:Dr. Nirupama Yechoor, Principal Investigator at Mass General Hospital and leader of the Bugher Collaborative.Dr. Devanshi Choksi, neurologist and colleague of Dr. Yechoor at Mass General.Rachel Kitagawa and Sofia Constantinescu, neurology postgraduates from Yale University.We dive into:The Bugher Collaborative: Its mission, the partnership between Mass General, Yale, and UCSF, and how it addresses equity in stroke care.Research Highlights: Insights into how socioeconomic status, access to care, and community support affect stroke outcomes.Yale's Findings: Key demographic differences uncovered through their research and what they reveal about health equity.The Road Ahead: Next steps for the collaborative and their vision for improving stroke care.Magic Wand Wishes: What each guest would change to improve stroke prevention and recovery if they had unlimited resources.This conversation builds on our discussion of the 2024 ASA Stroke Prevention Guidelines, offering a deeper dive into the intersection of health equity and stroke care.Resources and Links:Learn more about the Bugher CollaborativeDr. Nirupama Yechoor's BioDr. Devanshi Choksi's BioRachel Kitagawa's BioSofia Constantinescu's BioSupport Our Show! Thank you for helping us to continue to make great content. We appreciate your generosity! Support the showShow credits:Music intro credit to Jake Dansereau. Our intro welcome is the voice of Caroline Goggin, a stroke survivor and our first podcast guest! Please listen to her inspiring story on Episode 2 of the podcast.Connect with Us and Share our Show on Social:Website | Linkedin | Twitter | YouTube | FacebookKnow Stroke Podcast Disclaimer: Our podcast and media advertising services are for informational purposes only and do not constitute the practice of medical advice, diagnosis or treatment.

Dr. Sandra Hassink is joined by Dr. Lauren Fiechtner, the Director of Nutrition at MassGeneral Hospital for Children in the Division of Gastroenterology and Nutrition. She is also the Associate Professor of Pediatrics at Harvard Medical School. Together they discuss early feeding and food introduction.   Related Resources: • Building a Foundation for Healthy Active Living Modules (tinyurl.com/bdd5tsu6) • Healthy Active Living From Birth to Age 2, Resource Portal (tinyurl.com/4e7zvfnd) • The Role of the Pediatrician in the Promotion of Healthy, Active Living (tinyurl.com/5n8xv2du)

We must all be compassionate. You never know what someone else is going through. - Keely Krantz Keely Krantz got her start in PR, eventually leading the launch of high-profile, global brands. A proud Boston College graduate, she was fortunate to have a mentor who had broken through glass ceilings and believed in passing it on. Says Keely “Janet Diederichs at Edelman Public Relations in Chicago challenged me to be someone I would never have aspired to if it hadn't been for her guidance. I learned to be bold and aggressive.” At the height of Keely's career, she became a mom and decided to stay at home with her kids, choosing parenthood and volunteerism over a career. It was this devotion to community and the greater good that inspired Keely and her husband Jason to make the largest gift in the history of Mass General Hospital cancer research history last year. Says Keely: “We don't want to see small, incremental changes. We want to see fundamental, monumental, landscape-changing breakthroughs in the treatment of cancer, and we are willing to take big risks at the Krantz Family Research Center on physician-scientists who have big, aggressive ideas. We want to swing for the fences.” A few months later, Keely launched her next big chapter as the founder of the O'Dell Women's Center www.odellwomenscenter.com in Springfield, Massachusetts. Named after her 98-year-old grandmother, who was a maternity nurse in the community for 40 years, the O'Dell Center is a first-of-its-kind in Springfield with 10,000 square feet of collaborative space that houses Dress for Success/Western Mass and other non-profits that advance educational and career opportunities for low-income women. In just one year, $250,000 in grants have been awarded. For Keely, this new chapter is the culmination of a story rooted in faith and the lessons of her parents. “Anything is possible” are three words I heard all the time when I was growing up. Says Keely. “I want to be a connector, surrounded by the mantra that respect and kindness go hand in hand. I want to do good.” For 23 minutes of inspiration, just hit that download button. #women #community #cancer @massgeneralcancercenter

This is a conversation with Dr. David Amaral, a distinguished professor at the MIND Institute and scientific director of Autism BrainNet, and Dorothy Frisch, an activist and supporter of the program. Autism BrainNet is funded by the Simons Foundation to collect and study postmortem brain samples from individuals with autism to understand the neurological basis of the disorder better. Currently, there are no biomarkers for autism, so studying the brains and accomplishments of those who had autism can lead to a better understanding of the abilities and challenges seen on the autism spectrum. David explains, "We went to the Simons Foundation and, with their support, have established a network in the United States. We have three collection sites: one at the UC Davis Mind Institute in Sacramento, one at UT Southwestern in Dallas, Texas, and one at the Mass General Hospital in Boston, where a postmortem brain donation can be sent. Those brains are then prepared in ways that will facilitate all kinds of research both now and in the future. We have developed this resource to foster autism research throughout the world. What we are seeing now that we've just celebrated our 10th anniversary is that we've collected nearly 400 brain donations so far, and we're seeing an increasing demand from researchers worldwide to get access to that resource." Dorothy elaborates, "I was the main support person for my older cousin, Gregory Blackstock, for a couple of decades. He needed a lot of executive function help. He lived on his own but couldn't make critical decisions very well. As long as everything went along without any hitch, he was generally fine. But as he got older and experienced more physical infirmities, then I needed to step up more. So then he was very obviously autistic, so it was kind of peripherally interesting to me." "One of his savant traits was that he was an incredible artist. He also spoke many languages that he picked up by ear. He had a perfect pitch and learned the accordion, but he could easily transfer that information to playing the organ and the piano. He had almost total recall of anything that crossed his path that interested him. And so, just being around him and being involved with furthering his artistic career gave me further insights about the people I met who were interested in autism."   #AutismBrainNet #BrainDonation #AutismResearch #Autism #BrainResearch autismbrainnet.org Download the transcript here  

David explains, "We went to the Simons Foundation and, with their support, have established a network in the United States. We have three collection sites: one at the UC Davis Mind Institute in Sacramento, one at UT Southwestern in Dallas, Texas, and one at the Mass General Hospital in Boston, where a postmortem brain donation can be sent. Those brains are then prepared in ways that will facilitate all kinds of research both now and in the future. We have developed this resource to foster autism research throughout the world. What we are seeing now that we've just celebrated our 10th anniversary is that we've collected nearly 400 brain donations so far, and we're seeing an increasing demand from researchers worldwide to get access to that resource." Dorothy elaborates, "I was the main support person for my older cousin, Gregory Blackstock, for a couple of decades. He needed a lot of executive function help. He lived on his own but couldn't make critical decisions very well. As long as everything went along without any hitch, he was generally fine. But as he got older and experienced more physical infirmities, then I needed to step up more. So then he was very obviously autistic, so it was kind of peripherally interesting to me." "One of his savant traits was that he was an incredible artist. He also spoke many languages that he picked up by ear. He had a perfect pitch and learned the accordion, but he could easily transfer that information to playing the organ and the piano. He had almost total recall of anything that crossed his path that interested him. And so, just being around him and being involved with furthering his artistic career gave me further insights about the people I met who were interested in autism."   #AutismBrainNet #BrainDonation #AutismResearch #Autism #BrainResearch autismbrainnet.org Listen to the podcast here

Nishi Vootukuru (@Nishi_Vootukuru) and Dr. Ezra Schwartz (@ezraschwartz10) interview Dr. William Shutze and Dr. Anahita Dua (@AnahitaDua) to discuss the Get a Pulse on PAD Campaign.   The Get a Pulse on PAD initiative (#PulseonPAD), launched in February, 2024, is a patient education and advocacy campaign designed to increase the understanding of peripheral artery disease's risk factors and potential symptoms.     Dr. Shutze is a vascular surgeon with Texas Vascular Associates in Dallas, Texas and the Secretary of the SVS. Dr. Shutze completed his medical studies at Baylor University after completing general surgery residency at University of Alabama in Birmingham. Dr. Shutze returned to Baylor to complete his vascular fellowship. Dr. Shutze is one of the Get a Pulse on PAD initiative's chairs and a leading expert in PAD. He has actively published in the field with over 100 abstracts and articles, with his most recent work focusing on prosthetics, and advocating for successful prosthetic referral after amputation.    Dr. Dua is a vascular surgeon at Mass General Hospital and associate professor at Harvard Medical School. At Mass General, she is the director of the Vascular Lab, co-director of the Peripheral Artery Disease Center and Limb Evaluation and Amputation Program (LEAPP), associate director of the Wound Care Center, director of the Lymphedema Center and director of clinical research for the division of vascular surgery. She serves as the Editor-in-Chief of Journal of Vascular Surgery-Vascular Insights. Dr. Dua completed her undergraduate medical studies at the Aberdeen University School of Medicine in Aberdeen, Scotland. She then completed her general surgery residency at the Medical College of Wisconsin and vascular fellowship at Stanford University Hospital. She holds multiple master's degrees including degrees in trauma sciences and business administration in healthcare management. She also completed certificate programs at the Massachusetts Institute of Technology in health economics and outcomes research as well as in drug and device development. Dr. Dua is a prolific researcher, researcher, and advocate, with much of her work centered on PAD. She furthers patient care not only through research but through her political work as Founder of the Healthcare for Action political action committee (PAC) and member of the SVS PAC Steering Committee.    Special thank you to Jacob Soucey (@JacobWSoucy)   Resources: https://www.secondscount.org/get-a-pulse-pad https://evtoday.com/news/pad-pulse-alliance-survey-highlights-disconnect-in-public-knowledge-of-pad-risks Association of Black Cardiologists (ABC) Society for Cardiovascular Angiography & Interventions (SCAI) Society of Interventional Radiology (SIR) CardioVascular Coalition (CVC) Outpatient Endovascular and Interventional Society (OEIS) https://vascular.org/advocacy/political-action-committee https://evtoday.com/articles/2021-may/the-arc-act-fighting-amputation-via-legislation https://evtoday.com/articles/2006-may/EVT0506_10.html#:~:text=The%20Screening%20Abdominal%20Aortic%20Aneurysm,screening%20as%20a%20Medicare%20benefit CLariTI Study: Natural Progression of High-Risk Chronic Limb-Threatening Ischemia Socioeconomic and hospital-related predictors of amputation for critical limb ischemia  ARC Act of Congress Painkiller: TV Series  Congressman Payne  SAAAVE Act   Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.  

WBZ NewsRadio's Chaiel Schaffel reports.

This episode will explore hospitals, health care, and sustainability. Today, my guest is Dr. Jonathan Slutzman. Dr. Slutzman is the Director of the Center for the Environment and Health and Medical Director for Environmental Sustainability at Massachusetts General Hospital. We discuss this critical topic and the significant sustainability initiatives that the Mass General Hospital is leading toward a greener future for the good of patients, society, and the planet.

In this Leveling Up Episode of the PRS Global Open Deep Cuts Podcast, Dr. John Semple discusses his unusual pathway into medicine, three dimensional thinking, prepectoral breast reconstruction, the use of allograft and synthetic meshes, fat grafting in radiated breasts, some tips to make fat harvest easier, how to be a good mentor and a good leader, and how he got involved in climate science. Read a recent classic PRS Global Open article by Dr. Semple and co-authors, “Patient Outcomes after Fat Grafting to the Radiated Chest Wall before Delayed Two-stage Alloplastic Breast Reconstruction”: https://bit.ly/SempleFatGrafting  Dr. John Semple is a Professor in the Department of Surgery at the University of Toronto, and the head of the division of plastic surgery at Women's College Hospital. He is also an adjunct faculty member at the wilderness Medicine Program at Mass General Hospital in Boston, and an adjunct professor at the Ontario College of Art and Design, where was a former chair of the Board of Governors. He trained in art at OCAD and became a fully trained medical illustrator, then went into medicine, training in plastic surgery at the University of Toronto and then completing a microsurgery fellowship at the Toronto General Hospital. He is a past president of the Canadian Society of Plastic Surgeons, and received the Lavina Lickley Lifetime achievement award form the department of surgery at the University of Toronto. He also has a keen interest in mountaineering - and has been to Everest North Col 4 times, and has published numerous papers on the effects of climate change in the Himalayas.  Your host, Dr. Puru Nagarkar, is a board-certified plastic and hand surgeon, and Assistant Professor of Surgery at the University of Texas Southwestern Medical Center in Dallas. #PRSGlobalOpen #DeepCutsPodcast #PlasticSurgery #LevelingUp

In this episode, Chris Koddermann interviews two members of the Center for the Neuroscience of Psychedelics at Mass General Hospital: founding director, author, and co-founder of three drug development companies, Dr. Jerry Rosenbaum; and psychiatrist and associate director and director of cognitive neuroscience, Sharmin Ghaznavi, MD, Ph.D. Rosenbaum and Ghaznavi bonded over an interest in rumination, and wondered: How could the plasticity-inducing effects of psychedelics change these negative loops people find themselves in? How important is the ability to break out of those loops – and learn new patterns – when our concept of self is so central to who we are? Ghaznavi is studying the effects of psilocybin on rumination and scanning patients at multiple times throughout the process to track data we still don't really have: how psychedelic-induced neuroplasticity changes over time, and why. They discuss: How much of a role the default mode network takes in the therapeutic benefits of psychedelics: Is it overblown? Hyperscanning, which involves scanning two individuals at the same time, looking for potential concordance in signal and/or an increased alliance between the therapist and patient The Schultes Legacy Project and the work of Stephen Haggarty to explore the potential of largely unstudied psychoactive plants Critiques of the recent ruling on Lykos and MDMA-assisted therapy and the clash between the FDA and the advisory committee: Were they really on the same page? The false dichotomy of neuroscience vs. patient experience: Does the subjective experience actually increase plasticity and other measurable benefits? and more! For links, head to the show notes page.

In this episode of Research Renaissance, host Deborah Westphal dives into a fascinating conversation with Dr. Sudeshna Das, Associate Professor of Neurology at Mass General Hospital and Harvard Medical School. Dr. Das is a pioneer in the field of biomedical informatics and a 2022 Toffler Scholar. Her work focuses on developing tools for multi-scale data integration from molecular to clinical data and applying data science approaches to study neurodegenerative diseases, particularly Alzheimer's disease.Guest Introduction: Dr. Sudeshna DasDr. Sudeshna Das is an Associate Professor of Neurology at Mass General Hospital and Harvard Medical School. She specializes in biomedical informatics and has a keen interest in developing tools for integrating diverse data sets, from molecular to clinical, to understand complex diseases like Alzheimer's. Dr. Das has a rich background in engineering and computational biology, making significant contributions to the field of drug discovery and neurodegenerative disease research.Key Discussion PointsCareer Motivation and Journey:Dr. Das shares her early inspiration to cure cancer, driven by personal experiences with family members who had the disease.Her transition from engineering to biomedical informatics and the unique challenges and opportunities she faced as a female engineer in India.Biomedical Informatics and Data Integration:Explanation of biomedical informatics, bioinformatics, and computational biology.The importance of integrating large, high-dimensional data sets and real-world data for research.Challenges in managing and analyzing big data and high-velocity data.Alzheimer's Disease Research:The focus on understanding the roles of different cell types in Alzheimer's disease, particularly astrocytes, and their progression from protective to exhausted states.The significance of recent findings on the role of T cells in Alzheimer's disease and their potential as therapeutic targets.Future of Alzheimer's Research:The promise of new technologies like spatial transcriptomics and artificial intelligence in advancing Alzheimer's research.The potential of AI tools, such as graph neural nets, to model disease pathways and predict effective treatments for individual patients.The long-term goal of developing personalized treatments for Alzheimer's disease.Mentoring and Funding:Dr. Das's commitment to mentoring young researchers and her approach to guiding students through complex research landscapes.The role of foundations like the Karen Toffler Charitable Trust in providing crucial funding for preliminary research.Stay tuned for more episodes of Research Renaissance by subscribing to our podcast. For further information and updates, visit our website at TofflerTrust.org. We welcome your thoughts and suggestions, so feel free to reach out! Until then, onward and upward.To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

We kicked off the program with four news stories and different guests on the stories we think you need to know about!World Lung Cancer Day is coming up (8/1), and only 6% of Americans eligible for screenings actually get them. Dr. Efren Flores - thoracic radiologist at Mass General Hospital joined Dan to discuss.Boneless Chicken Wings Can Have Bones After All, Ohio Supreme Court Rules! John Rizvi – The Patent Professor and Dan review this ruling.Survey: 70% of parents say back-to-school shopping is too expensive! Bill Dendy – Financial Strategist looked at the expenses. New England athletes as they go for gold in the Paris Olympics! More than 40 athletes with local roots or college ties will vie for glory in this year's Games. Amin Touri Boston Globe Multiplatform Editor and Web Producer checked in! Ask Alexa to play WBZ NewsRadio on #iHeartRadio!

On this episode of Ropes & Gray's podcast series, Decoding Digital Health, Christine Moundas, a health care partner and co-chair of the firm's digital health initiative, is joined by Dr. Bernardo Bizzo, a senior director at Mass General Brigham AI and assistant professor of radiology in the Department of Radiology at Mass General Hospital. Dr. Bizzo discusses his work in the field of digital health and AI, including the development and clearance of AI products by the FDA. They also explore the promising aspects of AI in health care and the challenges involved in developing and deploying AI tools. 

Food insecurity has been a growing problem in Massachusetts for years, especially since the start of the COVID pandemic. Inflation hasn't helped, with food prices skyrocketing at the grocery store and at local restaurants. A new report from the Greater Boston Food Bank in collaboration with Mass General Brigham takes a closer look at the factors driving this concerning trend. Catherine D'Amato, President and CEO of the Food Bank, and Dr. Lauren Fiechtner, Director of Nutrition at the Mass General Hospital for Children, break down the highlights of the report with Nichole and share resources for those who are in need.

Anna Handorf, MD, sheds light on the innovative concept of Tiny Talks in the latest episode of the Faculty Factory Podcast. Tiny Talks serve as a novel medical education tool, designed to deliver concise, impactful virtual chalk talks. Dr. Handorf spearheaded Tiny Talks to help residents overcome scheduling conflicts that often lead to missed educational opportunities. The core objective of Tiny Talks is to distill lengthy lectures into brief, engaging presentations lasting seven minutes or less. Dr. Handorf is an instructor at Harvard Medical School and a pediatric hospitalist at Newton Wellesley Hospital in Newton, Massachusetts. As a former medical education research fellow at Mass General Hospital and Harvard Medical School, she penned an insightful article titled “Let's Chalk About It: Introducing the TinyTalks Curriculum, a Paradigm for Short, Virtual Chalk Talks,” published in Academic Medicine in March 2024. In this week's Faculty Factory Podcast interview, Dr. Handorf elaborates on the structured approach, encompassing a hook, frame, and delivery, essential for crafting an effective Tiny Talk. Learn More Follow Dr. Handorf: https://x.com/AnnaHandorf Email: ahandorf@mgb.org Read the article from Academic Medicine: https://journals.lww.com/academicmedicine/abstract/9900/let_s_chalk_about_it__introducing_the_tinytalks.816.aspx?utm_source=sfmc&utm_medium=email&utm_campaign=amexpress&utm_content=newsletter

This week, Dr. Scott Sigman sits down with Dr. Kevin Raskin, Associate Professor and Chief of Oncology at Mass General Hospital. Here, they discuss his training in musculoskeletal oncology, the passion and team approach he shares with his patients, and more.

Curious about the forces driving healthcare pricing and access? Join us for an enlightening conversation with Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah's upbringing in a family passionate about policy and social justice laid the foundation for her impactful career in health policy. We explore her educational journey from Smith College to Brandeis University's Heller School, and how her professional experiences in clinical research and biopharmaceutical consulting shaped her path to ICER.Unravel the complex world of health technology assessment (HTA) in the US as Sarah breaks down the challenges and opportunities within a fragmented healthcare system. ICER's pivotal role in evaluating new medical technologies is discussed in depth, including its interactions with international agencies like the UK's NICE. Sarah sheds light on ICER's evolution from a small initiative within Mass General Hospital to a powerful voice in global HTA practices, emphasizing the importance of fair pricing, patient access, and sustainable innovation funding.Equity in healthcare takes center stage as Sarah introduces ICER's updated value assessment framework. Learn about new tools like the clinical trial diversity rating and the Health Improvement Distribution Index (HIDI) designed to promote representation of diverse populations in clinical trials. We also tackle the high costs and value-based pricing of innovative treatments, including gene and cell therapies, and the necessity of evolving payment systems to ensure continuous innovation. Tune in to gain a comprehensive understanding of the pressing challenges and future directions in healthcare pricing, equity, and access.Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

Dr. Alessio Fasano, who is considered the world's leading expert in celiac disease and gluten-related disorders, returns for his second appearance on STEM-Talk. Although just 2 million Americans have celiac disease, an estimated 20 million Americans suffer from gluten sensitivity. Alessio is a professor and director of the Mucosal Immunology and Biology Research Center at Massachusetts General Hospital. In addition to celiac disease and gluten-related disorders, Alessio's research is also focused on the microbiome, intestinal permeability and autoimmune disorders, which he discussed in his first interview on STEM-Talk, episode 20. Since Alessio's first appearance on STEM-Talk in 2016, he has published two books, “Gluten Freedom” and “Gut Feelings: The Microbiome and Our Health,” which we discuss in today's interview. We also talk to Alessio about an exciting new project that's bringing together an international consortium of researchers and scientists for a long-term study that will follow infants who are genetically at risk of developing celiac. Alessio is a researcher and physician who wears many hats. He is the director of the Center for Celiac Research and Treatment and chief of the Division of Pediatric Gastroenterology and Nutrition at Mass General Hospital. He also is a professor of pediatrics at Harvard Medical School and a professor of nutrition at Harvard's T.H. Chan School of Public Health. Show notes: [00:03:58] Marcas opens the interview welcoming Alessio back to STEM-Talk, mentioning that since his last appearance he has written two books: Gluten Freedom and Gut Feelings: The Microbiome and Our Health. Marcas asks Alessio how he became interested in pediatrics and gastroenterology. [00:05:42] Ken mentions that Alessio moved to the U.S. in the 1990s and spent 20 years in Maryland at the Center for Vaccine Development in Baltimore. Ken goes on to mention that while Alessio was there, he founded The Center for Celiac Research in 1996, and in 2003, Alessio accepted an offer to join Massachusetts General Hospital. Ken asks how that move came about. [00:08:53] Marcas asks about Alessio's early career working on cholera, where he discovered the zonula occuldens toxin, the bacteria that causes cholera. Marcas asks Alessio to talk about this finding and the insights he gleaned from it. [00:16:03] Ken asks about Alessio's discovery of zonulin, which is the molecule that modulates gut permeability in humans. Ken asks Alessio to share how this discovery led him to investigate celiac disease, which is triggered by gluten. [00:20:25] Ken asks Alessio what his thoughts are on why the medical community, historically, has not taken celiac disease seriously. [00:24:08] Marcas mentions that as we age, there is evidence that the gut becomes leakier, which is highly related to chronic inflammation. Marcas asks Alessio whether this happens to the gut over time due to diet and lifestyle rather than the typical aging process. [00:28:45] Ken mentions that there has been an increase in the diagnosis of celiac disease. Ken asks Alessio if that is due to an actual increase in the prevalence of the disease, or is it tied to a growing appreciation that clinicians have now for the disease? [00:29:32] Marcas mentions that Alessio's book, Gluten Freedom, which he co-authored with his colleague Susie Flaherty, was referred to by the Celiac Disease Foundation as “a must have,” and “an excellent reference for those with gluten related disorders.” Marcas asks Alessio about this reception to his book. [00:31:24] Marcas mentions that the only viable treatment for individuals with celiac disease has been a gluten-free diet, with pharmaceutical companies having had little interest until recently in investigating the disease. Now there are more than 20 drug therapies in development for celiac. Marcas asks Alessio about the progress being made to develop pharmacological interventions for celiac.

Dr. Lisa Wong joins us for Episodes 8...and 9! Marlon sits down with Dr. Lisa Wong, pediatrician, musician, arts advocate, and author. She is the Co-Founder of the Arts and Humanities Initiative at Harvard Medical School, pediatrician at Milton Pediatric Associates, and an assistant clinical professor of pediatrics at Harvard Medical School. Dr. Wong also co-founded and serves as associate co-director of the Arts and Humanities Initiative, and the former president and a current violinist in the Longwood Symphony Orchestra, Boston's medical community ensemble. 

America's military must return our service members back to society ready to lead. Special operators are given the best tools in the military to do their jobs. They're also completely immersed into the special forces lifestyle with almost no distractions. Yet when they leave service, they're often left to themselves to find the right tools and to figure out what training they need to be successful in the next chapter. Two of America's most important organizations have partnered to bring our Veterans the best tools and training all wrapped up into an immersive, life changing program. For the third episode of our 2023 Army Navy Game tailgate series Fran Racioppi sat down with retired Brigadier General Jack Hammond, CEO of Home Base. Home Base is founded and supported by the Boston Red Sox and Mass General Hospital; a formidable team dedicated to winning and solving the most complex challenges in medicine and athletic performance.Home Base provides leading edge clinical care to the medical challenges faced by our veterans; including the effects of prolonged blast exposure, mental trauma, diabetes and even cancer. Veterans train directly with the best medical and athletic performance professionals in the industry with one goal in mind; return our military personnel back to society ready to perform at the highest level and continue to lead others. Take a listen, watch or read our conversation…and whether you're from Beantown or not, this is a Red Sox game you want to be a part of. The Jedburgh Podcast and the Jedburgh Media Channel are an official program of The Green Beret Foundation. Learn more on The Jedburgh Podcast Website. Subscribe to us and follow @jedburghpodcast on all social media. Watch the full video version on YouTube. Highlights:0:00 Welcome to the Army Navy Game Tailgate3:50 Home Base is built by the Boston Red Sox & Mass General7:06 Two months of therapy in two weeks11:18 How Home Base is treating Operator Syndrome16:38 How to support Home Base17:50 Proven results of the programQuotes: “When you look at the opportunity with those two powerhouse organizations and what the potential is to actually bend the curve and make a difference; they had me at hello.” (5:30) “We have access to the best clinical resources in the world. Bar none.” (6:12) “We created this 14-day intensive clinical program…that compresses two years of therapy into two weeks.” (8:55)“We're gonna be able to figure out what are the downstream chronic illnesses associated with concussive injury.” (13:49) “If you don't have the tools to do a job, it's like a monkey trying to change a tire with a screwdriver.” (19:50)

What is silent reflux? Find out in this episode of the MindBodySpace podcast, hosted by Dr. Juna. Every last Friday of the month, she is joined by her guest Dr. April Hirschberg to discuss evidence backed ways to decrease stress and increase resilience. Dr. April is a board certified psychiatrist specializing in lifestyle and mind-body medicine at Mass General Hospital, Harvard Medical School. They delve into how stress management and healthy lifestyle choices play a critical role in combating mental and physical health issues. This episode particularly focuses on gastroesophageal reflux disease (GERD), its symptoms, consequences, and misdiagnosis. They share personal experiences and insights into how stress exacerbates digestive issues, the significance of the gut-brain axis, and the role of the enteric nervous system. Practical advice is offered on managing stress through breathing exercises, mindfulness, proper diet, hydration, and the importance of not eating late to prevent reflux. Additionally, they emphasize the critical nature of seeking medical advice for persistent symptoms and the benefits of incorporating movement and enjoyable activities into daily routines for overall well-being. 00:00 Unveiling the Mystery: Why Stop Eating Early? 00:16 Welcome to the MindBodySpace Podcast 00:21 Stress Management with Dr. Hirschberg 01:31 The Gut-Brain Connection and Stress Impact 01:47 Misdiagnosed Reflux 07:40 Lifestyle Changes and Managing Reflux 15:15 Mindful Eating and Stress Reduction Techniques 22:15 Embracing Movement and Self-Care for Digestive Health 27:32 Closing Thoughts and Encouragement --- Support this podcast: https://podcasters.spotify.com/pod/show/mindbodyspace/support

In this episode of Oncology Brothers, join hosts Drs. Rahul and Rohit as they dive into the management of colon cancer with special guest Dr. Aparna Parikh, a medical oncologist from Mass General Hospital. Dr. Parikh shares insights on the treatment algorithm for colon cancer, including the use of circulating tumor DNA and the latest advancements in treatment options. From localized disease to metastatic space, the discussion covers key aspects of managing colon cancer. Tune in to learn about the evolving landscape of colon cancer treatment and the importance of personalized patient-centered care. Don't miss out on this informative episode with the Oncology Brothers and Dr. Aparna Parikh!

Tune in for a deep chat about psychedelic research, psychedelic assisted therapies, trauma healing, and more! Our guest Elowyn Samadhi, PhD (she/they) is a licensed clinical psychologist who specializes in the treatment of PTSD and other trauma-related disorders. She works in private practice and at Sage Integrative Health, a holistic psychedelic clinic in the Bay Area. Elowyn served as an independent rater for the Phase II and III MAPS MDMA trials for 4 years and began providing post-IV ketamine integration in 2015 at Mass General Hospital. She completed ketamine-assisted psychotherapy training with Polaris Insight Center and the MAPS MDMA-Assisted Therapy training. She also completed the UC-Berkeley Psilocybin Advanced Facilitator Training under the mentorship of Dr. Susana Bustos and is qualified to provide legal psilocybin services in Oregon. Dr. Samadhi serves as lead psilocybin therapist for the UCSD phantom limb pain clinical trial and has trained several of the co-therapists. She has guest lectured for Alchemy Community Therapy Center in Oakland and Beckley Academy, and supervises and mentors several psychedelic therapists-in-training. Elowyn is in her final year of the 3-year Somatic Experiencing training. Dr. Samadhi has a passion for teaching somatic therapy, safe and reparative touch work, as well as the ritual and spiritual praxis of guiding. Elowyn is biracial and bisexual and the bedrock of her spiritual path is non-dual, tantric, animistic, and pagan. We talk about psychedelic assisted healing modalities, the current research on psychedelics, MAPs, neuroplasticity, trauma healing,   Elowyn: https://www.elowynsamadhiphd.com/ https://tetheredhealing.com/   Past episode mentioned: https://slutsscholars.libsyn.com/198-the-war-on-drugs-with-ifetayo-harvey-of-thepoc-psychedelic-collective     FOLLOW US  Twitter Instagram Facebook Send questions, comments, stories, rants to: SlutsAndScholars@gmail.com Sluts And Scholars is a production of sluts and scholars media.   Loving disclaimer:  Sluts and Scholars is a podcast produced by Sluts & Scholars Media, LLC. It is a shame free educational podcast made for your entertainment and informational desires only. The podcast, any opinions we share, and any resources including social media and emails from us are not therapy, medical care or professional advice and do not create a patient-client relationship. None of the information, opinions, suggestions, resources or exercises mentioned in this podcast should be used without clearance from your health care provider. All opinions, information and ideas expressed by the guests are solely their own. If you need emergency mental health or medical help, please call 911 or 988 or go to your nearest emergency center. We hope you enjoy the show. 

When Jesse Janelle was in elementary school, she experienced a lot of anxiety. When feeling panicked, she went to the nurses' office, visiting there regularly. Jesse didn't know it then, but this is where her personal and professional development journey began. One day, 11-year-old Jesse was in the nurse's office having a particularly bad panic attack. The nurse called in the guidance counselor, who was asked to help sometimes. Jesse must have been extra anxious this time because the guidance counselor shook her by the shoulders and yelled, “Stop it right now,” in her face. At that moment, Jesse became disassociated from her body. Her thoughts separated from her ‘felt sense': her ability to know what was happening in her body. Jesse later understood this to be her sense of self-trust. Going into high school and then college, Jesse was high-performing. Attending Boston College, she got straight A's. Because she wasn't feeling connected to her body, she intellectualized many of her struggles. Jesse studied psychology and meditation, attaching deep academic and intellectual perspectives to those arenas. Around her graduation from college, Jesse began to connect with those areas in a felt way, enabling her to be more in touch with who she really was. Jesse's professional career began as an intern at Harvard Medical School's Institute of Coaching in its founding years, where she got immersed in evidence-based coaching research. As her experience and expertise grew, she consulted and coached leaders in top organizations such as McKinsey, Mass General Hospital, The Walt Disney Company, and Amazon.  Today, Jesse is the founder and CEO of . She is an ICF-certified transformational coach and speaker. Jesse has distilled her learnings from her work in leadership development, psychology, ontology, somatics, and spirituality into a coaching method she calls Soul Sessions. This method is grounded in metaphor coaching and intuitive inquiry. This method can be learned and applied independently of a professional coaching session. Using a surprising tool, tarot cards, Jesse helps professionals access and unlock the power of their intuition to make better decisions faster. In this week's learn more about Jesse's journey: Jesse was selected in 2022 for the inaugural cohort of Forefront, powered by Marshall Goldsmith and the 100 coaches, for her impact on the field of leadership development. In 2023, she delivered her TEDx talk, .   Learn more and connect with Jesse here:  Save 7 hours a week with a 7-minute daily tarot self-coaching practice: